AYTU - Aytu BioScience, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.5700
+0.0400 (+2.61%)
At close: 4:00PM EDT

1.6400 +0.07 (4.46%)
After hours: 7:38PM EDT

Stock chart is not supported by your current browser
Previous Close1.5300
Open1.4300
Bid1.5800 x 4000
Ask1.5800 x 28000
Day's Range1.3800 - 1.6200
52 Week Range0.3400 - 2.9900
Volume18,792,627
Avg. Volume16,069,487
Market Cap123.108M
Beta (5Y Monthly)3.45
PE Ratio (TTM)N/A
EPS (TTM)-1.1660
Earnings DateMay 11, 2020 - May 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.88
  • Top Ranked Momentum Stocks to Buy for April 2nd
    Zacks

    Top Ranked Momentum Stocks to Buy for April 2nd

    Top Ranked Momentum Stocks to Buy for April 2nd

  • ACCESSWIRE

    Aytu BioScience Announces Receipt of Initial Shipment of 100,000 COVID-19 IgG/IgM Point-of-Care Rapid Tests; Additional 500,000 Tests on Order

    Initial Shipment of 2-10 Minute COVID-19 Rapid Tests Received at Company's Englewood, Colorado Facility ENGLEWOOD, CO / ACCESSWIRE / April 1, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU),(the "Company"), ...

  • Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?

    Is (AYTU) Outperforming Other Medical Stocks This Year?

  • ACCESSWIRE

    AYTU Announces Delay of Annual Meeting of Stockholders Due to Colorado's "Shelter in Place" Order Related to the COVID-19 Crisis

    ENGLEWOOD, CO / ACCESSWIRE / March 30, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that its annual meeting of stockholders originally scheduled to be held on March 31, 2020 at 10:00 a.m. MST will be delayed to a later date to be determined by its Board of Directors (the "Annual Meeting"). The Company hopes to have the Annual Meeting by April 25, 2020 so that the record date for determining shareholders entitled to vote will remain unchanged. The Annual Meeting is being delayed due to the public health impact of the coronavirus pandemic (COVID-19) and the "shelter in place" order from the Governor of the State of Colorado.

  • Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher
    Zacks

    Aytu BioScience (AYTU) in Focus: Stock Moves 6.4% Higher

    Aytu BioScience (AYTU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • ACCESSWIRE

    Aytu BioScience Regains Compliance with NASDAQ Minimum Bid Price Requirement

    ENGLEWOOD, CO / ACCESSWIRE / March 25, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant ...

  • Aytu BioScience to Issue Coronavirus Rapid Test in North America
    Zacks

    Aytu BioScience to Issue Coronavirus Rapid Test in North America

    Aytu BioScience (AYTU) expands the right to distribute and commercialize the COVID-19 IgG/IgM rapid test across the United States, Canada and Mexico. Stock jumps.

  • The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics
    Zacks

    The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics

    The Zacks Analyst Blog Highlights: Danaher, Quidel, Aytu BioScience, QIAGEN and Co-Diagnostics

  • FDA Gives Aytu OK To Distribute Rapid COVID-19 Test, Company Expects To Receive 100,000 Tests This Week
    Benzinga

    FDA Gives Aytu OK To Distribute Rapid COVID-19 Test, Company Expects To Receive 100,000 Tests This Week

    Shares of Aytu Bioscience Inc (NASDAQ: AYTU), which announced earlier this month a deal to distribute a COVID-19 test, were rallying Monday after the company announced FDA approval for distribution of the test. The Engelwood, Colorado-based specialty pharma company said it has received confirmation from the FDA that it may begin distribution of its COVID-19 IgG/IgM Rapid Test throughout the U.S.The test, according to Aytu, is intended for professional use and delivers results in 2-10 minutes at the point-of-care.It is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the new coronavirus in human whole blood, serum or plasma."This point-of-care test has been validated in a 126-patient clinical trial and is CE marked," according to Aytu. Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Aytu said it expects to receive its first shipment of 100,000 tests at a Colorado warehouse this week. The company said it is in talks with health care distributors, health care institutions, medical practices and government agencies to quickly begin distributing the tests into the U.S. health care supply chain."With product now in transit to our warehouse in Colorado we're optimistic that we can have test kits ready for sale in the very near term," CEO Josh Disbrow said in a statement. The stock was trading 25% higher at $1.70 at the time of publication. Related Links:The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus 8 Biotechs With Coronavirus Vaccines In Development See more from Benzinga * The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals * GenMark Diagnostics Files For Emergency Use Authorization For COVID-19 Test * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Aytu BioScience Submits Notice of Commercialization to the FDA, Allowing for Company's Distribution of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test

    ENGLEWOOD, CO / ACCESSWIRE / March 23, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation from the U.S. Food and Drug Administration (FDA) that the company may begin distribution of its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test throughout the United States. The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers results between 2 and 10 minutes at the point-of-care.

  • ACCESSWIRE

    Aytu Announces $20 Million Registered Direct Offering Priced At-the-Market

    ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of an aggregate 12,539,187 shares of Aytu's common stock and warrants to purchase an aggregate of up to 12,539,187 shares of common stock, at a combined purchase price of $1.595 per share and associated warrant, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds to Aytu from this offering are expected to be approximately $20 million, before deducting the placement agent's fees and other offering expenses payable by Aytu.

  • ACCESSWIRE

    Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico

    ENGLEWOOD, CO / ACCESSWIRE / March 19, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it extended its distribution right to commercialize the clinically validated and commercially used coronavirus 2019 (COVID-19) IgG/IgM Rapid Test. The test has been licensed from L.B. Resources, Limited (a Hong Kong Corporation). The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers clinical results between 2 and 10 minutes at the point-of-care.

  • ACCESSWIRE

    Aytu BioScience Announces Acceleration of U.S. Availability of COVID-19 IgG/IgM Rapid Test Based on Updated FDA Policy

    Updated FDA Policy Likely Enables Near-Term Availability of COVID-19 Test in the U.S. ENGLEWOOD, CO / ACCESSWIRE / March 17, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that the company intends to expedite the U.S. launch of its recently licensed COVID-19 IgG/IgM Point-of-Care Rapid Test in light of yesterday's updated FDA policy on coronavirus diagnostic testing. On March 16, 2020 the FDA announced, "as part of our ongoing and aggressive commitment to address the coronavirus outbreak, the FDA updated a policy originally issued on Feb. 29 on diagnostic testing for coronavirus (COVID-19) in order to achieve more rapid testing capacity in the U.S. We believe the unprecedented policy set forth in today's updated guidance, which addresses laboratories and commercial manufacturers, will help address these urgent public health concerns by helping to expand the number and variety of diagnostic tests..."

  • ACCESSWIRE

    Aytu BioScience's Coronavirus Rapid Test Featured on NBC and Fox News (VIDEOS): ''Englewood Company Says It Can Get COVID-19 Test Results in 2-10 Minutes"; "2-Minute COVID-19 Test Results? Denver-Area Company Wants to Deliver That Promise"

    ENGLEWOOD, CO / ACCESSWIRE / March 16, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced ...

  • The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals
    Benzinga

    The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

    The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus. I-Mab ADR (NASDAQ: IMAB)The Shanghai-based biopharma said Friday it is initiating the development pf TJM2 to treat cytokine storms in severe and critically ill patients caused by COVID-19. TJM2 is a neutralizing antibody against human granulocyte-macrophage colony stimulating factor, an important cytokine that plays a key role in acute and chronic inflammation.The company said it is awaiting FDA acceptance of an investigational new drug application. La Jolla Pharmaceutical Company (NASDAQ: LJPC)La Jolla said Friday that it is providing Giapreza in Italy for compassionate use in patients with septic shock associated with COVID-19. Giapreza was approved by the FDA in 2017 as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.It was later approved by the European Commission for treating refractory hypotension in adults with septic or other distributive shock.The drug, though approved by the EC, is not yet commercially available.Italian law allows authorized medicines for life-threatening and rare illnesses to be made available prior to commercial launch, according to La Jolla. Enanta Pharmaceuticals Inc (NASDAQ: ENTA)Enanta Pharma said Friday it has initiated a program to discover direct-acting antiviral drug candidates for treating patients infected with the coronavirus. The company said it is drawing upon its expertise in virology.The company is also screening compounds from its antiviral compound library for potential activity against COVID-19.See also: How Close Are Biotechs To Bringing A COVID-19 Treatment To Market? CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF)Canadian biotech Can-Fite said Friday it is entering into a collaborative research agreement with the Lewis Katz School of Medicine at Templeton University, Philadelphia, to support research directed by Dr. Kamel Khalili, who is exploring the antiviral activity of piclidenoson on the coronavirus' viral load in a mammalian cell model system as a first step.Piclidenoson is Can-Fite's investigational Phase 3 asset currently being evaluated for rheumatoid arthritis and moderate-to-severe psoriasis.Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY)Roche said Friday that the FDA has issued an Emergency Use Authorization for the cobas SARS-CoV-2 Test.Eli Lilly And Co (NYSE: LLY)Lilly said Thursday that it's collaborating with AbCellera, a privately held company developing therapeutic antibodies, to co-develop antibody products for treating COVID-19.Meanwhile, Opko Health Inc. (NASDAQ: OPK) and Aytu Bioscience Inc (NASDAQ: AYTU) announced updates to their COVID-19 initiatives.Opko said Friday that its BioReference Labs subsidiary has begun accepting specimens for testing of COVID-19 from health care providers, clinics and health systems throughout the U.S.The company has announced a partnership with the New York State Department of Health for the first public drive-through testing facility on the East Coast. BioReference Labs is also planning to offer up to 5,000 tests a day at additional testing sites to be set up next week.Aytu announced the establishment Friday of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public.The company said Tuesday that it clinched a distribution deal for a COVID-19 IgG/IgM Rapid Test.Biotech Price Action * La Jolla was rallying 8.92% to $4.15 * Can-Fite shares were rallying 5.26% to $1.40. * Lilly shares were advancing 5.09% to $132.44. * Opko Health was jumping 39.08% to $1.98. * Aytu was slipping 20.65% to $1.46. * OTC-listed Roche shares were up 7.77% at $38.43. Related Link: Inovio Continues To Rip Higher On Gates Foundation Funding For DNA Vaccine Delivery Device See more from Benzinga * The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO * The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • ACCESSWIRE

    Aytu BioScience Establishes COVID-19 IgG/IgM Rapid Test Product Inquiry Procedure for Healthcare Professionals and Institutions

    ENGLEWOOD, CO / ACCESSWIRE / March 13, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today the establishment of a COVID-19 inquiry procedure to ensure the company adequately responds to inbound inquires from professionals and the public. In order to streamline and effectively capture the significant number of inbound inquiries related to the COVID-19 IgG/IgM Rapid Test, the company requests healthcare professionals, institutions, and other interested parties to send email inquiries to a COVID-19-dedicated email address.

  • Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?
    Zacks

    Aytu BioScience, Inc. (AYTU) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Aytu BioScience, Inc. (AYTU).

  • Benzinga

    Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 11, 2020: TDOC, GNMK, HLT, MEET, AYTU

    Benzinga Pro's Stocks To Watch For Wednesday * Teladoc (TDOC) \- Shares of this virtual healthcare services provider were up about 5% Wednesday morning and up about 34% over the last month. As more events and schools are being cancelled, U.S. citizens are beginning to consider the possibility they will need to stay at home at some point over the next month or so. * GenMark Diagnostics (GNMK) \- Shares were up 14% amid news the company submitted an emergency use authorization for its coronavirus test, ePlex. * Hilton Worldwide (HLT) \- The stock was down 4% following news the company withdrew its FY20 guidance amid the coronavirus outbreak. * Meet Group (MEET) \- Reported a Q4 beat on earnings and a miss on sales. Shares were up about 1% ahead of the open. * Aytu BioScience (AYTU) \- Tuesday's biggest winner (up 489%) following news of a coronavirus rapid test distribution deal for within the U.S., shares were down about 5% to $1.92 in pre-market action as the company announced an offering. Aytu offered 7.826 million share common stock offering at $1.15/share. On Tuesday, about 184 million shares of Aytu traded; the stock normally trades about 3.3 million shares.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Wed., Mar. 4, 2020: JWN, VIR, CMG, AHPI, GNMK(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
    Benzinga

    The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * Aytu Bioscience Inc (NASDAQ: AYTU) (announced a deal to distribute COVID-19 test) * Centogene NV (NASDAQ: CNTG) * Forty Seven Inc (NASDAQ: FTSV)Down In The Dumps(Biotech Stocks Hitting 52-week lows on March 10) * Accelerate Diagnostics Inc (NASDAQ: AXDX) * Adamas Pharmaceuticals Inc (NASDAQ: ADMS) * Adaptive Biotechnologies Corp (NASDAQ: ADPT) * ADMA Biologics Inc (NASDAQ: ADMA) * Aeglea Bio Therapeutics Inc (NASDAQ: AGLE) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Affimed NV (NASDAQ: AFMD) * Akari Therapeutics PLC (NASDAQ: AKTX) * Akcea Therapeutics Inc (NASDAQ: AKCA) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) * Alkermes Plc (NASDAQ: ALKS) * Allena Pharmaceuticals Inc (NASDAQ: ALNA) * ANCHIANO THERAP/S ADR (NASDAQ: ANCN) * AngioDynamics, Inc. (NASDAQ: ANGO) * ANI Pharmaceuticals Inc (NASDAQ: ANIP) * Anixa Biosciences Inc (NASDAQ: ANIX) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Aptevo Therapeutics Inc (NASDAQ: APVO) * Aptinyx Inc (NASDAQ: APTX) * Assertio Therapeutics Inc (NASDAQ: ASRT) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * AxoGen, Inc Common Stock (NASDAQ: AXGN) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Bausch Health Companies Inc (NYSE: BHC) * Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) * BENITEC BIOPHAR/S ADR (NASDAQ: BNTC) * BioLife Solutions Inc (NASDAQ: BLFS) * bluebird bio Inc (NASDAQ: BLUE) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Capricor Therapeutics Inc (NASDAQ: CAPR) * Celcuity Inc (NASDAQ: CELC) * Cerecor Inc (NASDAQ: CERC) * Chembio Diagnostics Inc (NASDAQ: CEMI) * Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) * Enochian Biosciences Inc (NASDAQ: ENOB) * Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) * Eton Pharmaceuticals Inc (NASDAQ: ETON) * Evolus Inc (NASDAQ: EOLS) * Exicure Inc (NASDAQ: XCUR) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Five Prime Therapeutics Inc (NASDAQ: FPRX) * Gossamer Bio Inc (NASDAQ: GOSS) * Gritstone Oncology Inc (NASDAQ: GRTS) * GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) * Heron Therapeutics Inc (NASDAQ: HRTX) * Incyte Corporation (NASDAQ: INCY) * INmune Bio Inc (NASDAQ: INMB) * Integra Lifesciences Holdings Corp (NASDAQ: IART) * Invivo Therapeutics Holdings Corp (NASDAQ: NVIV) * Jaguar Health Inc (NASDAQ: JAGX) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) * Kura Oncology Inc (NASDAQ: KURA) * Lantheus Holdings Inc (NASDAQ: LNTH) * TapImmune Inc. common stock (NASDAQ: MRKR) * MediciNova, Inc. (NASDAQ: MNOV) * Meridian Bioscience, Inc. (NASDAQ: VIVO) * Misonix Inc (NASDAQ: MSON) * Moleculin Biotech Inc (NASDAQ: MBRX) * Myriad Genetics, Inc. (NASDAQ: MYGN) * Neovasc Inc (NASDAQ: NVCN) * Neurometrix Inc (NASDAQ: NURO)ccccc * Neuronetics Inc (NASDAQ: STIM) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * Orchard Therapeutics PLC - ADR (NASDAQ: ORTX) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pieris Pharmaceuticals Inc (NASDAQ: PIRS) * Plus Therapeutics Inc (NASDAQ: PSTV) * Polarityte Inc (NASDAQ: PTE) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Precipio Inc (NASDAQ: PRPO) * Radius Health Inc (NASDAQ: RDUS) * Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) * Rubius Therapeutics Inc (NASDAQ: RUBY) * SAGE Therapeutics Inc (NASDAQ: SAGE) * Stealth BioTherapeutics Corp (NASDAQ: MITO) * Stemline Therapeutics Inc (NASDAQ: STML) * SurModics, Inc. (NASDAQ: SRDX) * Synlogic Inc (NASDAQ: SYBX) * T2 Biosystems Inc (NASDAQ: TTOO) * Tcr2 Therapeutics Inc (NASDAQ: TCRR) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) * Unum Therapeutics Inc (NASDAQ: UMRX) * Vericel Corp (NASDAQ: VCEL) * X4 Pharmaceuticals Inc (NASDAQ: XFOR) * Xeris Pharmaceuticals Inc (NASDAQ: XERS) * X T L Biopharmaceuticals Ltd (NASDAQ: XTLB) * ZIOPHARM Oncology Inc. (NASDAQ: ZIOP)See Also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Mallinckrodt's Global Opioid Settlement Agreement Endorsed By New York State Mallinckrodt PLC (NYSE: MNK) said the New York State Attorney General Letitia James lent support to the company's previously announced global opioid settlement, joining 47 other states and U.S. Territory Attorneys General.The State of New York and Suffolk County, together with Mallinckrodt and SpecGx LLC, have jointly filed a motion to remove the companies from the New York State opioid trial.In pre-market trading, shares were rising 13.24% to $2.48.Kamada to Work On Treatment for Severely Ill COVID-19 Patients Israeli plasma-derived biopharma Kamada Ltd. (NASDAQ: KMDA) said it plans to initiate the development of an Anti-COVID-19 polyclonal immunoglobin using is its proprietary plasma derived IgG platform technology as a potential treatment for severely ill coronavirus patients."We are working with the Israeli regulatory authorities and local medical institutions to advance our program," said Amir London, CEO of Kamada.In pre-market trading, shares were up 6.23% to $5.80.FDA Approves Bristol-Myers' Opdivo-Yervoy Combo For Liver Cancer Bristol-Myers Squibb Co's (NYSE: BMY) said the FDA approved its sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma, previously treated with Bayer AG (OTC: BAYRY) and Onyx Pharma's Nexavar.Phio Pharma Announces Agreement to Develop Immune Enhancers Phio Pharmaceuticals Corp (NASDAQ: PHIO) has reached a new agreement with Medigene relating to its previously announced research collaboration with Helmholtz Zentrum Munchen to develop novel candidates for the use of Intasyl compounds in adoptive cell therapy to enhance immune function.The new agreement provides for Medigene contributing expertise regarding clinical development and proprietary research material. The company also has an option to an exclusive license for potential immune cell enhancers against certain fee payments.Phio shares rallied 15.30% to $3.24 in after-hours trading.NuCana's Ovarian Cancer Drug Shows Favorable Disease Control In Midstage Study NuCana PLC (NASDAQ: NCNA) announced preliminary results from part one of the Phase 2 study of single-agent Acelarin in difficult-to-treat patients with platinum-resistant ovarian cancer, which showed that out of the 45 evaluable patients, one patient achieved a complete response and two patients achieved partial responses, while 16 achieved stable disease."We are pleased with this favorable disease control rate and Acelarin's ability to achieve confirmed complete and partial responses in this very heavily pre-treated patient population," said Hugh Griffith, CEO of NuCana.Separately, the company reported fourth-quarter results showing a wider loss.View more earnings on MNKNuCana shares rose 7.25% to $7.25 in after-hours trading.Sophiris Bio Shares to Be Delisted From Nasdaq, Effective March 12 Sophiris Bio Inc (NASDAQ: SPHS), which is evaluating its topsalysin in late-stage clinical trials for urological diseases, said the Nasdaq Officer of General Counsel informed the company that the Nasdaq Hearing Panel has determined to delist its shares from the Nasdaq. Trading in the company's shares are to be suspended, effective at the open of business March 12.The company said it expects its shares to be eligible for trading on the OTC.The delisting comes in the wake of the company flouting listing standards pertaining to the minimum $2.5 million stockholder's equity requirement.The stock plummeted 39.58% to 35 cents in the after-hours trading.J&J's Lung Cancer Therapy Gets Breakthrough Designation Johnson & Johnson (NYSE: JNJ) said its Janssen unit's JNJ-61186372 has been granted Breakthrough Therapy Designation by the FDA for the treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.Roche's Biomarker-based Screening Test For Cervical Cancer Approved by FDARoche Holdings AG Basel ADR (OTC: RHHBY) said the FDA approved its CINtec PLUS Cytology, as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for HPV using the cobas 4800 HPV Test.Altimmune Soars Despite No NewsAltimmune Inc (NASDAQ: ALT) shares were sharply higher in after-hours trading, although there was no release from the company.Earnings RA Medical Systems Inc (NYSE: RMED) reported a decline in is fourth-quarter revenues from $2 million in 2018 to $1.4 million in 2019. The net loss per share narrowed from $1.18 to 72 cents. Analysts estimated a loss of $1.15 per share.The stock plunged 39.72% to 85 cents in after-hours trading.Fulgent Genetics Inc's (NASDAQ: FLGT) fourth-quarter revenues climbed 48% year-over-year to $8.4 million and the company reported non-GAAP EPS of 4 cents, in line with the consensus estimate.The stock 4.92% to $14.50 in after-hours trading.Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported fourth-quarter revenues of $2.07 million in 2019 compared to no revenues a year ago. The net loss per share narrowed from 16 cents to 5 cents, while analysts estimated a loss of 7 cents per share.The stock slipped 5.21% to 91 cents in after-hours trading.Offerings Kala Pharmaceuticals Inc (NASDAQ: KALA) said it has priced its underwritten public offering of 16 million shares at $7.89 per share, for generating gross proceeds of $126.2 million. The company expects the offering to close March 13.In premarket trading Wednesday, Kala shares were adding 11.53% to $8.80.On The Radar Earnings • Xeris Pharma (before the market open) • Liquidia Technologies Inc (NASDAQ: LQDA) (before the market open) • Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) (before the market open) • INmune Bio Inc (NASDAQ: INMB) (before the market open) • Clearside Biomedical Inc (NASDAQ: CLSD) (after the close) • Calithera Biosciences Inc (NASDAQ: CALA) (after the close) • Unity Biotechnology Inc (NASDAQ: UBX) (after the close) • Navidea Biopharmaceuticals Inc (NYSE: NAVB) (after the close) • Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) (after the close) • BioLife Solutions Inc (NASDAQ: BLFS) (after the close) • Dynavax Technologies Corporation (NASDAQ: DVAX) (after the close) • Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) • Pfenex Inc (NYSE: PFNX) (after the close) • Arcturus Therapeutics Ltd (NASDAQ: ARCT) (after the close) • Novavax, Inc. (NASDAQ: NVAX) (after the close) • Global Cord Blood Corp (NYSE: CO) (after the close)See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues * The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers
    Zacks

    Wall Street Rises on Trump's Stimulus: ETF & Stock Gainers

    Trump plans to offer fiscal stimulus to counter coronavirus-related economic fallout. As the Wall Street rallied on the hopes, these ETFs and stocks gained massively.

  • ACCESSWIRE

    Aytu Announces $9.0 Million Registered Direct Offering Priced At-the-Market

    ENGLEWOOD, CO / ACCESSWIRE / March 11, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor for the purchase and sale of 7,826,087 shares of Aytu's common stock (or common stock equivalent), at a purchase price of $1.15 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds to Aytu from this offering are expected to be approximately $9.0 million, before deducting the placement agent's fees and other estimated offering expenses payable by Aytu. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, and to continue the commercialization of the Company's prescription and consumer health products.

  • ACCESSWIRE

    Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test

    ENGLEWOOD, CO / ACCESSWIRE / March 10, 2020 / Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it signed an exclusive distribution agreement for the right to commercialize a clinically validated and commercially used coronavirus 2019 (COVID-19) IgG/IgM Rapid Test. The test has been licensed from L.B. Resources, Limited (a Hong Kong Corporation), which licensed North American rights from product developer Zhejiang Orient Gene Biotech Co., Ltd. The test is intended for professional use and delivers clinical results between 2 and 10 minutes at the point-of-care. This exclusive agreement grants Aytu the exclusive right to distribute the product in the United States for a period of three years, with additional three-year autorenewals thereafter.

  • Thomson Reuters StreetEvents

    Edited Transcript of AYTU earnings conference call or presentation 13-Feb-20 9:30pm GMT

    Q2 2020 Aytu BioScience Inc Earnings Call